PD-(L)1 x VEGF Bispecific Plus ADC Combos Progress In Leaps And Bounds In 2025

 
• By Dexter Jie Yan
  
PD-(L)1/VEGF-targeting bispecific antibodies combined with antibody-drug conjugates are advancing by leaps and bounds in the clinic. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D